BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares growth accelerates
Q1 FY2026 weighted avg shares of 31.14M shares rose 32.5% year over year, ahead of the +25.4% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +15.0% a year.
Context
- Weighted avg shares increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +32.5% holds above the trailing-twelve-month pace of +25.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 31.14M USD
- Year-over-year change
- +87.2%
- 4-year CAGR
- +11.0%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.14M | +87.2% |
| FY2024 | 2024-12-31 | 16.64M | -18.8% |
| FY2023 | 2023-12-31 | 20.49M | +0.0% |
| FY2022 | 2022-12-31 | 20.49M | +0.0% |
| FY2021 | 2021-12-31 | 20.49M | — |
Weighted Avg Shares vs competitors
How BBOT compares with its peers on the latest reported figures
- BBOT's LTM Mar 2026 weighted avg shares of 27.33M shares is the lowest of the 10 companies compared; the peer median is 60.16M shares.
- Its year-over-year change of +25.4% is the 4th highest of 10, against a peer median of +13.3%.
- Over three fiscal years its annual growth of +15.0% compares with a peer median of +13.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | 145.89M | +32.5% | +9.8% | |
| LTM Aug 2026 | 106.95M | +29.6% | +21.3% | |
| LTM Mar 2026 | 75.43M | +13.3% | +23.1% | |
| LTM Jun 2026 | 74.94M | +5.1% | +7.6% | |
| LTM Sep 2026 | 60.16M | +14.0% | +0.6% | |
| LTM Mar 2026 | 54.96M | +27.5% | +16.9% | |
| LTM Mar 2026 | 48.8M | +11.9% | +28.3% | |
SEPNSepterna, Inc. | LTM Sep 2026 | 45.24M | +9.8% | — |
| LTM Mar 2026 | 28.59M | -2.5% | -0.4% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | 27.33M | +25.4% | +15.0% |
| Peer median (excluding BBOT) | 60.16M | +13.3% | +13.4% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 0 | 0 | 56.29M | 73.11M | 121.2M |
| Selling, General & Admin | 43.36K | 3.52K | 8.49M | 7.76M | 24.62M |
| Operating Expenses | 43.36K | 3.52K | 64.77M | 80.86M | 145.82M |
| Depreciation & Amortization | 74.33K | 3.52K | 92K | 208K | 610K |
| EBITDA | (43.36K) | (3.52K) | (64.68M) | (80.66M) | (145.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.36K) | (3.52K) | (64.77M) | (80.86M) | (145.82M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 72K | 8.46M | 11.34M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 0 | 0 | 72K | 8.18M | 11.78M |
| Income Before Tax | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (43.36K) | (3.52K) | (64.7M) | (74.28M) | (134.04M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.00) | 0.00 | (3.16) | 0.46 | (4.30) |
| EPS (Diluted) | (0.00) | (0.00) | (3.16) | 0.46 | (4.30) |
| Weighted Avg Shares | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
| Weighted Avg Shares (Diluted) | 20.49M | 20.49M | 20.49M | 16.64M | 31.14M |
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.